Abstract Details

Title Examining the impact of early versus late-onset multiple sclerosis on retinal structures

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 003

Objective To compare the impact of early versus late-onset multiple sclerosis (MS) on retinal structures.

Background Late-onset MS is characterized by more aggressive disease course and worse clinical outcomes than early-onset MS. Optical Coherence Tomography (OCT) is a fast, noninvasive tool utilized to quantify the thickness and volume of retinal structures.

Design/Methods Eighty-eight MS patients were included in this single-center retrospective study and split into two groups: 62 early-onset MS (diagnosed <50 years; mean age±SD: 37.7±9.4; mean DD±SD: 2.6±3.6) and 26 late-onset MS (diagnosed 51+ years; mean age±SD: 61.0±5.4; mean DD±SD:5.8±4.5). An OCT was performed to quantify the peripapillary retinal nerve fiber layer (pRNFL) thickness and volumetric macular scans. The pRNFL was segmented into quadrant thickness: superior (S), inferior (I), temporal (T), and nasal (N). Automated intra-retinal segmentation was performed to obtain the following macular volumes: total macular (TMV), papillomacular bundle (PMB), retinal nerve fiber (RNFL), ganglion cell + inner plexiform (GCIP), inner nuclear (INL), outer plexiform (OPL), and outer nuclear (ONL) layers. A generalized linear model was used for analysis with OCT parameters as the dependent variables and the MS onset category (early or late) as the independent variable. Age and disease duration were included as covariates (SPSS v26).

Results Our results yielded no significant differences in global pRNFL thickness and TMV and GCIP volumes between our early- and late-onset disease groups.

Conclusions Our findings suggest that there are no significant differences in the integrity of retinal structures between early- and late-onset multiple sclerosis patients. This indicates that time of diagnosis may not contribute greatly to worsened or more severe OCT outcomes.

Authors/Disclosures
Madeline Bross (Wayne State University) PRESENTER	Ms. Bross has nothing to disclose.
	No disclosure on file
Carla E. Santiago-Martinez (Wayne State University)	Ms. Santiago-Martinez has nothing to disclose.
Jacob C. Rube, MD (University Health Center)	Dr. Rube has nothing to disclose.
Samiksha Srivastava, MD (Wayne State University)	Dr. Srivastava has nothing to disclose.
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine)	Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.

��ɫ��

��ɫ��